Establishing a cryopreservation protocol for patient‐derived xenografts of prostate cancer
Abstract
Serially transplantable patient‐derived xenografts (PDXs) are invaluable preclinical models for studying tumor biology and evaluating therapeutic agents. As these models are challenging to establish from prostate cancer specimens, the ability to preserve them through cryopreservation has several advantages for ongoing research. Despite this, there is still uncertainty about the ability to cryopreserve PDXs of prostate cancer. This study compared three different cryopreservation protocols to identify a method that can be used to reproducibly cryopreserve a diverse cohort of prostate cancer PDX models.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Jun 18, 2019
- Source ID
- 10.1002/pros.23839
Entities
People
- Andrew Bakshi
- Andrew Ryan
- Ashlee K. Clark
- Daisuke Obinata
- David Clouston
- David Goode
- David Pook
- Declan G Murphy
- Eva Corey
- Gail Petuna Risbridger
- Hong Wang
- Jeremy Grummet
- John Kourambas
- John T Isaacs
- Laura H. Porter
- Mark Frydenberg
- Melissa Papargiris
- Mitchell G Lawrence
- Mural
- Peter S Nelson
- Renea A Taylor
- Sam Norden
- Shahneen K Sandhu
Organizations
- Congressionally Directed Medical Research Programs
- Endocrine Society of Australia
- Fred Hutchinson Cancer Center
- Monash Health
- Monash University
- Movember Foundation
- National Health and Medical Research Council
- TissuPath
- University of Melbourne
- University of Washington